Baird Financial Group
BMRN icon

Baird Financial Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Baird Financial Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,535
Closed -$1.17M – 1713
2023
Q2 		$1.17M Buy
13,535
+826
+6% +$77.7K ﹤0.01% 1069
2023
Q1 		$1.24M Sell
12,709
-13
-0.1% -$1.35K ﹤0.01% 1034
2022
Q4 		$1.32M Sell
12,722
-326
-2% -$30.6K ﹤0.01% 988
2022
Q3 		$1.11M Sell
13,048
-73
-0.6% -$6.5K ﹤0.01% 1013
2022
Q2 		$1.09M Sell
13,121
-4,368
-25% -$348K ﹤0.01% 1051
2022
Q1 		$1.35M Sell
17,489
-701
-4% -$58.7K ﹤0.01% 1025
2021
Q4 		$1.61M Sell
18,190
-176
-1% -$14.5K ﹤0.01% 1019
2021
Q3 		$1.42M Buy
18,366
+64
+0.3% +$5.05K ﹤0.01% 1068
2021
Q2 		$1.53M Sell
18,302
-267,677
-94% -$21.2M ﹤0.01% 1020
2021
Q1 		$21.6M Sell
285,979
-4,022
-1% -$329K 0.06% 280
2020
Q4 		$25.4M Buy
290,001
+3,892
+1% +$309K 0.08% 247
2020
Q3 		$21.8M Buy
286,109
+283,742
+11,987% +$28.7M 0.07% 253
2020
Q2 		$292K Sell
2,367
-54
-2% -$5.37K ﹤0.01% 1308
2020
Q1 		$204K Sell
2,421
-865
-26% -$74.5K ﹤0.01% 1329
2019
Q4 		$278K Sell
3,286
-31,407
-91% -$2.37M ﹤0.01% 1350
2019
Q3 		$2.34M Sell
34,693
-16,509
-32% -$1.27M 0.01% 730
2019
Q2 		$4.39M Sell
51,202
-5,601
-10% -$479K 0.02% 548
2019
Q1 		$5.05M Buy
56,803
+1,748
+3% +$162K 0.03% 444
2018
Q4 		$4.69M Buy
55,055
+6,133
+13% +$583K 0.03% 432
2018
Q3 		$4.83M Sell
48,922
-1,439
-3% -$144K 0.03% 453
2018
Q2 		$4.74M Buy
50,361
+4,762
+10% +$417K 0.03% 446
2018
Q1 		$3.7M Sell
45,599
-3,265
-7% -$280K 0.03% 481
2017
Q4 		$4.36M Sell
48,864
-10,987
-18% -$955K 0.03% 446
2017
Q3 		$5.57M Sell
59,851
-108
-0.2% -$9.54K 0.04% 396
2017
Q2 		$5.45M Buy
59,959
+709
+1% +$64.5K 0.04% 388
2017
Q1 		$5.2M Buy
59,250
+6,920
+13% +$616K 0.04% 391
2016
Q4 		$4.33M Buy
52,330
+9,209
+21% +$792K 0.04% 397
2016
Q3 		$3.99M Buy
43,121
+33,783
+362% +$3.18M 0.04% 415
2016
Q2 		$826K Buy
+9,338
New +$794K 0.01% 793

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Baird Financial Group's BMRN Position: Q3 2023 in Review

Baird Financial Group sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 13,535 shares — an estimated $1.17M sold.

Baird Financial Group first reported a position in BMRN in Q2 2016 and held it in 29 quarters. The position peaked at $25.4M in Q4 2020. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

  • Baird Financial Group reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Baird Financial Group sold 13,535 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $1.17M.
  • Baird Financial Group first reported a position in BioMarin Pharmaceuticals in Q2 2016 and held it in 29 quarters.
  • Baird Financial Group's BioMarin Pharmaceuticals position peaked at $25.4M in Q4 2020.
  • 519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Baird Financial Group's 13F filing for Q3 2023, filed 13 Nov 2023.